article · Sohag Medical Journal
Background:Clear cell renal cell carcinoma (ccRCC) is an aggressive urological malignancy. The aggressive potential of ccRCC is attributed to epithelial-mesechymal transition, which acquire the neoplastic cells more invasive properties. Membrane-Organizing Extension Spike Protein (Moesin/ MSN) plays an important role in controlling cellular morphology and motility. Aim:Evaluation of moesin expression in ccRCC and determine its cellular distribution, and then correlate its expression with certain clinicopathological variables.Methods:Archived formalin-fixed, paraffin-embedded ccRCC tissue blocks of 55 patients were obtained and sectioned. From each tissue block; 2 tissue sections were stained by hematoxylin and eosin (H&E) stain and anti-moesin immunohistochemical antibody. Results:Less differentiated cases of ccRCC with high WHO/ISUP grades were significantly associated with male sex (p= 0.023), presence of perirenal fat invasion (p< 0.001) and advanced tumor stages (p= 0.003).Moesin showed membranous localization in all enrolled cases. Membranous moesin expression was associated with high WHO/ISUP grades (p= 0.004), advanced tumor stages (p< 0.001), capsular and perirenal fat invasion (p= 0.001& p< 0.001) and presence of lymph nodes invasion (p< 0.001).Cytoplasmic redistribution of moesin was detected in 30 cases. Cytoplasmic moesin was correlated with capsular and perirenal fat invasion (p= 0.033& p= 0.001), tumors with high WHO/ISUP grades (p< 0.001), advanced tumor stages (p< 0.001) and presence of nodal metastasis (p= 0.002).Conclusion:Membranous overexpression of moesin and its cytoplasmic redistribution were detected in aggressive and less differentiated cases of clear cell renal cell carcinoma.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.21608/smj.2024.337520.1513
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.